{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:21:51Z","timestamp":1790022111001,"version":"4.0.1"},"reference-count":177,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Glycoconjugate vaccines have proven their worth in the protection and prevention of infectious diseases. The introduction of the Haemophilus influenzae type b vaccine is the prime example, followed by other glycoconjugate vaccines. Glycoconjugate vaccines consist of two components: the carrier protein and the carbohydrate antigen. Current carrier proteins are tetanus toxoid, diphtheria toxoid, CRM197, Haemophilus protein D and the outer membrane protein complex of serogroup B meningococcus. Carbohydrate antigens have been produced mainly by extraction and purification from the original host. However, current efforts show great advances in the development of synthetically produced oligosaccharides and bioconjugation. This review evaluates the advances of glycoconjugate vaccines in the last five years. We focus on developments regarding both new carriers and antigens. Innovative developments regarding carriers are outer membrane vesicles, glycoengineered proteins, new carrier proteins, virus-like particles, protein nanocages and peptides. With regard to conjugated antigens, we describe recent developments in the field of antimicrobial resistance (AMR) and ESKAPE pathogens.<\/jats:p>","DOI":"10.3390\/vaccines11020219","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T04:19:40Z","timestamp":1674101980000},"page":"219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Carriers and Antigens: New Developments in Glycoconjugate Vaccines"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7686-9632","authenticated-orcid":false,"given":"Robert M.F.","family":"van der Put","sequence":"first","affiliation":[{"name":"Intravacc, P.O. Box 450, 3720 AL Bilthoven, The Netherlands"},{"name":"Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-7656","authenticated-orcid":false,"given":"Bernard","family":"Metz","sequence":"additional","affiliation":[{"name":"Intravacc, P.O. Box 450, 3720 AL Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-3584","authenticated-orcid":false,"given":"Roland J.","family":"Pieters","sequence":"additional","affiliation":[{"name":"Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"ref_1","unstructured":"CDC (2022, September 29). History of Smallpox, Available online: https:\/\/www.cdc.gov\/smallpox\/history\/history.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-Immunological Studies on Conjugated Carbohydrate-Proteins: Ii. Immunological Specificity of Synthetic Sugar-Protein Antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J. Exp. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1128\/iai.52.2.519-528.1986","article-title":"Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates","volume":"52","author":"Schneerson","year":"1986","journal-title":"Infect. Immun."},{"key":"ref_4","first-page":"77","article-title":"Haemophilus influenzae type B polysaccharide-protein conjugates: Model for a new generation of capsular polysaccharide vaccines","volume":"47","author":"Schneerson","year":"1980","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1001\/jama.294.23.3019","article-title":"Immunological memory: The role of B cells in long-term protection against invasive bacterial pathogens","volume":"294","author":"Kelly","year":"2005","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1016\/j.vaccine.2009.06.013","article-title":"Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1016\/j.vaccine.2011.04.053","article-title":"Comparative effects of carrier proteins on vaccine-induced immune response","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1542\/peds.60.5.730","article-title":"Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland","volume":"60","author":"Peltola","year":"1977","journal-title":"Pediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00006454-198601000-00009","article-title":"First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants","volume":"5","author":"Koskela","year":"1986","journal-title":"Pediatr. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: Characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \"neglected valency\" - Potential and limitations","volume":"35","author":"Broker","year":"2017","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0008-8749(87)90008-6","article-title":"Epitopic suppression in synthetic vaccine models: Analysis of the effector mechanisms","volume":"104","author":"Schutze","year":"1987","journal-title":"Cell. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/285664a0","article-title":"Carrier-priming leads to hapten-specific suppression","volume":"285","author":"Herzenberg","year":"1980","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1128\/iai.59.3.1057-1064.1991","article-title":"Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine","volume":"59","author":"Barington","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/IAI.66.5.2093-2098.1998","article-title":"Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants","volume":"66","author":"Dagan","year":"1998","journal-title":"Infect Immun"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: A review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/nar\/12.10.4063","article-title":"The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197","volume":"12","author":"Giannini","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Broker","year":"2011","journal-title":"Biologicals"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","article-title":"Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use","volume":"28","author":"Shinefield","year":"2010","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1086\/527396","article-title":"Protein D of Haemophilus influenzae: A protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines","volume":"46","author":"Forsgren","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(06)68304-9","article-title":"Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study","volume":"367","author":"Prymula","year":"2006","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.4049\/jimmunol.145.9.3071","article-title":"Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine","volume":"145","author":"Donnelly","year":"1990","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/378744","article-title":"Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: Randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children","volume":"37","author":"Kilpi","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Micoli, F., Adamo, R., and Costantino, P. (2018). Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends. Molecules, 23.","DOI":"10.3390\/molecules23061451"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/infdis\/163.5.1040","article-title":"Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans","volume":"163","author":"Cryz","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/infdis\/170.4.834","article-title":"Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers","volume":"170","author":"Cross","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/IAI.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossaczka","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/iai.61.3.1023-1032.1993","article-title":"Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A","volume":"61","author":"Fattom","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1084\/jem.166.5.1510","article-title":"Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals","volume":"166","author":"Szu","year":"1987","journal-title":"J. Exp. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2016.06.039","article-title":"Preclinical studies on new proteins as carrier for glycoconjugate vaccines","volume":"34","author":"Tontini","year":"2016","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K","article-title":"Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: A model for new conjugate vaccines","volume":"31","author":"Falugi","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1128\/IAI.73.9.5835-5841.2005","article-title":"Combined conjugate vaccines: Enhanced immunogenicity with the N19 polyepitope as a carrier protein","volume":"73","author":"Baraldo","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10719-009-9259-4","article-title":"Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant","volume":"27","author":"Bongat","year":"2010","journal-title":"Glycoconj. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13526","DOI":"10.1073\/pnas.0803195105","article-title":"Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis","volume":"105","author":"Xin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/j.1460-2075.1988.tb02787.x","article-title":"A sequence pattern common to T cell epitopes","volume":"7","author":"Rothbard","year":"1988","journal-title":"EMBO J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nchembio.2007.25","article-title":"Robust immune responses elicited by a fully synthetic three-component vaccine","volume":"3","author":"Ingale","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"ref_40","first-page":"175","article-title":"Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenzae type B (Hib) conjugate vaccine","volume":"251","author":"Bixler","year":"1989","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/chem.200400903","article-title":"Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection","volume":"11","author":"Belot","year":"2005","journal-title":"Chemistry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.4049\/jimmunol.164.3.1625","article-title":"Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses","volume":"164","author":"Alexander","year":"2000","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.vaccine.2003.11.061","article-title":"Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE)","volume":"22","author":"Alexander","year":"2004","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0264-410X(98)00225-4","article-title":"Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein","volume":"16","author":"Michon","year":"1998","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pozzi, C., Wilk, K., Lee, J.C., Gening, M., Nifantiev, N., and Pier, G.B. (2012). Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046648"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3390\/toxins6041385","article-title":"Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity","volume":"6","author":"Romano","year":"2014","journal-title":"Toxins"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/acschembio.5b00247","article-title":"Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation","volume":"10","author":"Nilo","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1021\/acs.bioconjchem.5b00365","article-title":"Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide","volume":"26","author":"Nilo","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1128\/IAI.05484-11","article-title":"Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis","volume":"79","author":"Simon","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cbpa.2013.10.001","article-title":"Synthetic carbohydrate antigens for HIV vaccine design","volume":"17","author":"Wang","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1172\/JCI91192","article-title":"T cells control the generation of nanomolar-affinity anti-glycan antibodies","volume":"127","author":"Polonskaya","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/bs.mie.2017.06.032","article-title":"Glycoengineered Outer Membrane Vesicles as a Platform for Vaccine Development","volume":"597","author":"Valguarnera","year":"2017","journal-title":"Methods Enzymol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/vaccines8030540","article-title":"GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines","volume":"8","author":"Micoli","year":"2020","journal-title":"Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3389\/fmicb.2017.01053","article-title":"Outer Membrane Vesicles (OMVs) of Gram-negative Bacteria: A Perspective Update","volume":"8","author":"Jan","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age","volume":"18","author":"Labadie","year":"2000","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"770","DOI":"10.4049\/jimmunol.114.2_Part_2.770","article-title":"Immunologic properties of bacterial lipopolysaccharide (LPS): Correlation between the mitogenic, adjuvant, and immunogenic activities","volume":"114","author":"Skidmore","year":"1975","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/mi.2017.11","article-title":"Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model","volume":"10","author":"Liu","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/IAI.67.5.2552-2560.1999","article-title":"Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB","volume":"67","author":"Lehmann","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/biot.201400395","article-title":"Outer membrane vesicles as platform vaccine technology","volume":"10","author":"Stork","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6978","DOI":"10.1016\/j.vaccine.2019.01.076","article-title":"Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: Production and purification","volume":"37","author":"Gerritzen","year":"2019","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"719315","DOI":"10.3389\/fimmu.2021.719315","article-title":"Generalized Modules for Membrane Antigens as Carrier for Polysaccharides: Impact of Sugar Length, Density, and Attachment Site on the Immune Response Elicited in Animal Models","volume":"12","author":"Micoli","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/vaccines10071034","article-title":"GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A Streptococcus","volume":"10","author":"Palmieri","year":"2022","journal-title":"Vaccines"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e12192","DOI":"10.1002\/jev2.12192","article-title":"A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants","volume":"11","author":"Jiang","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"ref_67","first-page":"180","article-title":"Novel Simple Conjugation Chemistries for Decoration of GMMA with Heterologous Antigens","volume":"22","author":"Alfini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-019-0121-9","article-title":"Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230","volume":"4","author":"Scaria","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/fmb.09.10","article-title":"N-linked glycosylation in bacteria: An unexpected application","volume":"4","author":"Langdon","year":"2009","journal-title":"Future Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-019-0110-z","article-title":"Recent advances in the production of recombinant glycoconjugate vaccines","volume":"4","author":"Kay","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1126\/science.298.5599.1790","article-title":"N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli","volume":"298","author":"Wacker","year":"2002","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.analchem.1c04690","article-title":"Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry","volume":"94","author":"Nicolardi","year":"2022","journal-title":"Anal. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/02648725.2019.1703614","article-title":"Glycoconjugate vaccines: Some observations on carrier and production methods","volume":"35","author":"MacCalman","year":"2019","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41467-019-08869-9","article-title":"A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host","volume":"10","author":"Harding","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/vaccines10020212","article-title":"The Ongoing Journey of a Shigella Bioconjugate Vaccine","volume":"10","author":"Martin","year":"2022","journal-title":"Vaccines"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/glycob\/cwz044","article-title":"Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate","volume":"29","author":"Ravenscroft","year":"2019","journal-title":"Glycobiology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"18655","DOI":"10.1073\/pnas.1907833116","article-title":"A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae","volume":"116","author":"Feldman","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-018-0090-4","article-title":"A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13","volume":"3","author":"Reglinski","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"E3106","DOI":"10.1073\/pnas.1718341115","article-title":"Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies","volume":"115","author":"Stevenson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41541-017-0037-1","article-title":"Design and production of conjugate vaccines against S. Paratyphi A using an O-linked glycosylation system in vivo","volume":"3","author":"Sun","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8087916","DOI":"10.1155\/2018\/8087916","article-title":"An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia","volume":"2018","author":"Marshall","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acsinfecdis.9b00347","article-title":"Group A Streptococcus Cell Wall Oligosaccharide-Streptococcal C5a Peptidase Conjugates as Effective Antibacterial Vaccines","volume":"6","author":"Wang","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/vaccines9020139","article-title":"Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24111","DOI":"10.1021\/acsomega.1c07360","article-title":"Non-Native Amino Acid Click Chemistry-Based Technology for Site-Specific Polysaccharide Conjugation to a Bacterial Protein Serving as Both Carrier and Vaccine Antigen","volume":"7","author":"Kapoor","year":"2022","journal-title":"ACS Omega"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/infdis\/jiz357","article-title":"Conjugation of Different Immunogenic Enterococcal Vaccine Target Antigens Leads to Extended Strain Coverage","volume":"220","author":"Laverde","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1016\/j.vaccine.2022.07.011","article-title":"Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein","volume":"40","author":"Chang","year":"2022","journal-title":"Vaccine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e2200443","DOI":"10.1002\/adma.202200443","article-title":"Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae","volume":"34","author":"Deng","year":"2022","journal-title":"Adv. Mater."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"22037","DOI":"10.1038\/s41598-021-01549-z","article-title":"Rotavirus spike protein DeltaVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine","volume":"11","author":"Park","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/iub.2159","article-title":"Preparation and preclinical evaluation of two novel Staphylococcus aureus capsular polysaccharide 5 and 8-fusion protein (Hla-MntC-SACOL0723) immunoconjugates","volume":"72","author":"Ahmadi","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-020-00681-8","article-title":"Constructing conjugate vaccine against Salmonella Typhimurium using lipid-A free lipopolysaccharide","volume":"27","author":"Chiu","year":"2020","journal-title":"J. Biomed Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1038\/s41598-020-59711-y","article-title":"Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen","volume":"10","author":"Ou","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1038\/s41598-020-62185-7","article-title":"Elicitation of integrated immunity in mice by a novel pneumococcal polysaccharide vaccine conjugated with HBV surface antigen","volume":"10","author":"Qian","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1016\/j.vaccine.2020.04.080","article-title":"A unique algorithm for the determination of peptide-carrier protein conjugation ratio by amino acid analysis using intrinsic internal standard","volume":"38","author":"Yang","year":"2020","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.vaccine.2018.04.035","article-title":"Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever","volume":"36","author":"An","year":"2018","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Baliban, S.M., Curtis, B., Toema, D., Tennant, S.M., Levine, M.M., Pasetti, M.F., and Simon, R. (2018). Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice. PLoS Negl. Trop Dis., 12.","DOI":"10.1371\/journal.pntd.0006522"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1016\/j.vaccine.2018.09.052","article-title":"Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella","volume":"36","author":"Laird","year":"2018","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41565-020-0739-9","article-title":"Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health","volume":"16","author":"Fries","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.vaccine.2018.01.056","article-title":"Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells","volume":"36","author":"Basu","year":"2018","journal-title":"Vaccine"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.vaccine.2020.01.091","article-title":"Bacteriophage Qbeta virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus","volume":"38","author":"Basu","year":"2020","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/vaccines9070726","article-title":"Development of Bacteriophage Virus-Like Particle Vaccines Displaying Conserved Epitopes of Dengue Virus Non-Structural Protein 1","volume":"9","author":"Warner","year":"2021","journal-title":"Vaccines"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/vaccines9040395","article-title":"Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles","volume":"9","author":"Zha","year":"2021","journal-title":"Vaccines"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/vaccines7030072","article-title":"Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection","volume":"7","author":"Lim","year":"2019","journal-title":"Vaccines"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Sungsuwan, S., Wu, X., Shaw, V., Kavunja, H., McFall-Boegeman, H., Rashidijahanabad, Z., Tan, Z., Lang, S., Tahmasebi Nick, S., and Lin, P.H. (2022). Structure Guided Design of Bacteriophage Qbeta Mutants as Next Generation Carriers for Conjugate Vaccines. ACS Chem. Biol.","DOI":"10.1021\/acschembio.1c00906"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10719-021-09999-3","article-title":"On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines","volume":"38","author":"Prasanna","year":"2021","journal-title":"Glycoconj. J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/ijms222212538","article-title":"Chemoenzymatic Synthesis and Antibody Binding of HIV-1 V1\/V2 Glycopeptide-Bacteriophage Qbeta Conjugates as a Vaccine Candidate","volume":"22","author":"Zong","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1002\/anie.201915913","article-title":"Chemical Synthesis and Immunological Evaluation of a Pentasaccharide Bearing Multiple Rare Sugars as a Potential Anti-pertussis Vaccine","volume":"59","author":"Wang","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.vaccine.2018.12.073","article-title":"Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein","volume":"37","author":"Xu","year":"2019","journal-title":"Vaccine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"867119","DOI":"10.3389\/fbioe.2022.867119","article-title":"Biological Nanoparticles in Vaccine Development","volume":"10","author":"Curley","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_110","first-page":"71","article-title":"A library of protein cage architectures as nanomaterials","volume":"327","author":"Flenniken","year":"2009","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-981-13-9791-2_10","article-title":"Self-Assembly of Ferritin: Structure, Biological Function and Potential Applications in Nanotechnology","volume":"1174","author":"Chakraborti","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_112","first-page":"5378","article-title":"Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants","volume":"9","author":"Chen","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","article-title":"Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B","volume":"15","author":"Wang","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.1073\/pnas.1115485109","article-title":"Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin","volume":"109","author":"Zakeri","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1021\/acs.bioconjchem.0c00308","article-title":"An Apoferritin-Hemagglutinin Conjugate Vaccine with Encapsulated Nucleoprotein Antigen Peptide from Influenza Virus Confers Enhanced Cross Protection","volume":"31","author":"Wei","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.partic.2021.04.001","article-title":"Apoferritin nanoparticle based dual-antigen influenza conjugate vaccine with potential cross-protective efficacy against heterosubtypic influenza virus","volume":"64","author":"Sheng","year":"2022","journal-title":"Particuology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1016\/j.vaccine.2006.04.070","article-title":"Overlapping synthetic peptides as vaccines","volume":"24","author":"Jiang","year":"2006","journal-title":"Vaccine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1074\/jbc.M809456200","article-title":"Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells","volume":"284","author":"Zhang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ijbiomac.2022.09.180","article-title":"A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan","volume":"222","author":"He","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/acs.bioconjchem.1c00333","article-title":"Poly(hydrophobic amino acid) Conjugates for the Delivery of Multiepitope Vaccine against Group A Streptococcus","volume":"32","author":"Azuar","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/vaccines9091034","article-title":"Oral Peptide Vaccine against Hookworm Infection: Correlation of Antibody Titers with Protective Efficacy","volume":"9","author":"Shalash","year":"2021","journal-title":"Vaccines"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biologicals.2019.10.001","article-title":"Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice","volume":"62","author":"Haque","year":"2019","journal-title":"Biologicals"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/femsre\/fuy011","article-title":"Potential targets for next generation antimicrobial glycoconjugate vaccines","volume":"42","author":"Micoli","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"15672","DOI":"10.1021\/acs.chemrev.2c00021","article-title":"Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance","volume":"122","author":"Osterlid","year":"2022","journal-title":"Chem. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/acschembio.6b00084","article-title":"Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines","volume":"11","author":"Feng","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: Past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"108158","DOI":"10.1016\/j.pharmthera.2022.108158","article-title":"Recent advances and future perspectives on carbohydrate-based cancer vaccines and therapeutics","volume":"235","author":"Sorieul","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"15603","DOI":"10.1021\/acs.chemrev.1c01032","article-title":"Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments","volume":"122","author":"Shivatare","year":"2022","journal-title":"Chem. Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/ph12020084","article-title":"Developments in Carbohydrate-Based Cancer Therapeutics","volume":"12","author":"Hossain","year":"2019","journal-title":"Pharmaceuticals"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.4155\/fmc-2021-0109","article-title":"A systematic review of carbohydrate-based bioactive molecules for Alzheimer\u2019s disease","volume":"13","author":"Bajad","year":"2021","journal-title":"Future Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial Resistance in ESKAPE Pathogens","volume":"33","author":"Forde","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(22)00087-3","article-title":"The overlooked pandemic of antimicrobial resistance","volume":"399","author":"Laxminarayan","year":"2022","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.31729\/jnma.7174","article-title":"Antimicrobial Resistance: The Next Probable Pandemic","volume":"60","author":"Gautam","year":"2022","journal-title":"JNMA J. Nepal. Med. Assoc."},{"key":"ref_136","unstructured":"WHO (2022, November 11). Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-EMP-IAU-2017.12."},{"key":"ref_137","unstructured":"CDC (2022, November 11). 2019 AR Threats Report, Available online: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html#carp."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2468-2667(22)00225-0","article-title":"The burden of bacterial antimicrobial resistance in the WHO European region in 2019: A cross-country systematic analysis","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1128\/IAI.00149-09","article-title":"Further characterization of the epa gene cluster and Epa polysaccharides of Enterococcus faecalis","volume":"77","author":"Teng","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kalfopoulou, E., Laverde, D., Miklic, K., Romero-Saavedra, F., Malic, S., Carboni, F., Adamo, R., Lenac Rovis, T., Jonjic, S., and Huebner, J. (2019). Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci. Infect. Immun., 87.","DOI":"10.1128\/IAI.00276-19"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/07328303.2017.1390576","article-title":"Synthesis and immunological study of a wall teichoic acid-based vaccine against E. faecium U0317","volume":"36","author":"Zhou","year":"2017","journal-title":"J. Carbohydr. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fchem.2020.00258","article-title":"Conjugation of Synthetic Trisaccharide of Staphylococcus aureus Type 8 Capsular Polysaccharide Elicits Antibodies Recognizing Intact Bacterium","volume":"8","author":"Zhao","year":"2020","journal-title":"Front. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"843183","DOI":"10.3389\/fimmu.2022.843183","article-title":"Development of Klebsiella pneumoniae Capsule Polysaccharide-Conjugated Vaccine Candidates Using Phage Depolymerases","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/acscentsci.1c00656","article-title":"Synthetic Pseudaminic-Acid-Based Antibacterial Vaccine Confers Effective Protection against Acinetobacter baumannii Infection","volume":"7","author":"Wei","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/acsinfecdis.2c00184","article-title":"Synthesis and Immunogenicity of a Methyl Rhamnan Pentasaccharide Conjugate from Pseudomonas aeruginosa A-Band Polysaccharide","volume":"8","author":"Jamshidi","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10719-021-09985-9","article-title":"The development and characterization of an E. coli O25B bioconjugate vaccine","volume":"38","author":"Kowarik","year":"2021","journal-title":"Glycoconj. J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-97-3-344","article-title":"Vancomycin therapy for methicillin-resistant Staphylococcus aureus","volume":"97","author":"Sorrell","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_149","first-page":"269","article-title":"Vancomycin Resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1128\/CMR.17.1.218-234.2004","article-title":"Staphylococcus aureus capsular polysaccharides","volume":"17","author":"Lee","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddtec.2020.09.002","article-title":"Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-beta-(1-->6)-N-acetyl-d-glucosamine exopolysaccharide","volume":"35-36","author":"Gening","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fmicb.2020.01249","article-title":"The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive Klebsiella pneumoniae in a Multi-Country Collection","volume":"11","author":"Choi","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF02016559","article-title":"Progress in immunization against Klebsiella infections","volume":"2","author":"Cryz","year":"1983","journal-title":"Eur. J. Clin. Microbiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"15964","DOI":"10.1021\/acs.joc.0c01404","article-title":"A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against Klebsiella pneumoniae Serotype K2","volume":"85","author":"Ravinder","year":"2020","journal-title":"J. Org. Chem."},{"key":"ref_155","first-page":"73","article-title":"Capsular K-antigen-PLGA Nano conjugated Vaccine against Klebsiella pneumoniea pneumoniae K2O1 Infection","volume":"30","author":"Ghaderinia","year":"2022","journal-title":"J. Adv. Med. Biomed. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e2100549","DOI":"10.1002\/advs.202100549","article-title":"Production of a Promising Biosynthetic Self-Assembled Nanoconjugate Vaccine against Klebsiella Pneumoniae Serotype O2 in a General Escherichia Coli Host","volume":"8","author":"Peng","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Hegerle, N., Choi, M., Sinclair, J., Amin, M.N., Ollivault-Shiflett, M., Curtis, B., Laufer, R.S., Shridhar, S., Brammer, J., and Toapanta, F.R. (2018). Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203143"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"13973","DOI":"10.1002\/anie.201700964","article-title":"A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniae","volume":"56","author":"Seeberger","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.carres.2015.10.001","article-title":"Surface polysaccharides from Acinetobacter baumannii: Structures and syntheses","volume":"418","author":"Giguere","year":"2015","journal-title":"Carbohydr. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e0167422","DOI":"10.1128\/spectrum.01674-22","article-title":"Immune Response to Conjugates of Fragments of the Type K9 Capsular Polysaccharide of Acinetobacter baumannii with Carrier Proteins","volume":"10","author":"Rudenko","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/1751-7915.13770","article-title":"Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice","volume":"15","author":"Li","year":"2022","journal-title":"Microb. Biotechnol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1021\/jacs.8b04078","article-title":"Pseudaminic Acid on Exopolysaccharide of Acinetobacter baumannii Plays a Critical Role in Phage-Assisted Preparation of Glycoconjugate Vaccine with High Antigenicity","volume":"140","author":"Lee","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20121248","article-title":"The challenges and promises of new therapies for cystic fibrosis","volume":"209","author":"Pier","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1128\/jcm.25.5.824-826.1987","article-title":"Comparison of the Chinese schema and the International Antigenic Typing System for serotyping Pseudomonas aeruginosa","volume":"25","author":"Liu","year":"1987","journal-title":"J. Clin. Microbiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0305-4179(02)00024-4","article-title":"Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics","volume":"28","author":"Estahbanati","year":"2002","journal-title":"Burns"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/cc13697","article-title":"Pseudomonas aeruginosa serotypes in nosocomial pneumonia: Prevalence and clinical outcomes","volume":"18","author":"Lu","year":"2014","journal-title":"Crit. Care"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"152278","DOI":"10.1016\/j.imbio.2022.152278","article-title":"Protective effect of two new nanovaccines against Pseudomonas aeruginosa based on LPS and OPS: A comparison study","volume":"227","author":"Maleki","year":"2022","journal-title":"Immunobiology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.75.103004.142545","article-title":"Biosynthesis and assembly of capsular polysaccharides in Escherichia coli","volume":"75","author":"Whitfield","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1016\/j.vaccine.2020.06.024","article-title":"Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections","volume":"38","author":"Saade","year":"2020","journal-title":"Vaccine"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.vaccine.2011.06.001","article-title":"Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii","volume":"29","author":"McConnell","year":"2011","journal-title":"Vaccine"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1016\/j.vaccine.2008.07.004","article-title":"Outer membrane vesicles as acellular vaccine against pertussis","volume":"26","author":"Roberts","year":"2008","journal-title":"Vaccine"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/IAI.68.7.4189-4199.2000","article-title":"Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A","volume":"68","author":"Shang","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1574-6968.2000.tb08905.x","article-title":"A role for the bacterial outer membrane in the pathogenesis of Helicobacter pylori infection","volume":"182","author":"Keenan","year":"2000","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1574-6968.2012.02549.x","article-title":"Klebsiella pneumoniae secretes outer membrane vesicles that induce the innate immune response","volume":"331","author":"Lee","year":"2012","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/IAI.00433-10","article-title":"Naturally produced outer membrane vesicles from Pseudomonas aeruginosa elicit a potent innate immune response via combined sensing of both lipopolysaccharide and protein components","volume":"78","author":"Ellis","year":"2010","journal-title":"Infect. Immun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/acscentsci.1c01479","article-title":"The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella","volume":"8","author":"Smitsman","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"ref_177","unstructured":"FDA (2022, November 17). Vaccines Licensed for Use in the United States, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:10:11Z","timestamp":1760119811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":177,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["vaccines11020219"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11020219","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}